Inductive Quotient

The Clin'telligence Curve

From Foundations in AI to Intelligent Execution in Clinical Trials and Life Sciences

Boddu Sri Pavan

Table of Contents

1. Executive Summary

Artificial intelligence in clinical trials and life sciences has evolved from early rule-based expert systems into data-driven, language-capable, and scientifically impactful platforms. What began as decision-support tools such as MYCIN and INTERNIST-1 has progressed through statistical learning, deep learning, and foundation models into a new generation of systems that can support protocol design, patient identification, site selection, risk-based oversight, and translational research. This evolution was enabled by three major shifts: the digitisation of health data, the advancements in AI algorithms, and the growing availability of real-world, genomic, imaging, and clinical-text datasets.

In clinical development, AI is now creating the greatest value where trial complexity is highest and manual effort is least efficient. The strongest use cases are emerging in trial design optimisation, recruitment and retention, feasibility analysis, site intelligence, and risk-based monitoring. Published studies and reviews show that AI can help broaden eligibility analysis, improve patient-to-trial matching, and enhance site selection through real-world data and predictive modelling. At the same time, advances in scientific AI from protein structure prediction to AI-assisted molecule discovery are accelerating the connection between biology, translational insight, and clinical strategy.

The strategic implication is clear: AI is no longer peripheral to clinical and life sciences operations. It is becoming part of the operating model for how therapies are discovered, trials are designed, participants are identified, and quality is managed. However, long-term value will not come from adoption alone. It will come from disciplined deployment in environments that demand scientific validity, regulatory readiness, transparency, and human oversight. As frameworks such as WHO guidance on health AI and ICH E6(R3) reinforce risk-based, quality-by-design thinking, the organisations best positioned to lead will be those that combine innovation with governance, and automation with trust.

2. The Emergence of AI: Where It Started and Why It Matters?

Artificial intelligence began as a formal field, when the Dartmouth proposal and the Dartmouth Summer Research Project argued that learning, language, abstraction, and problem-solving could be described precisely enough for machines to simulate them. From that point onward, AI did not advance as one continuous line; it progressed in capability waves shaped by new data, new algorithms, and new computing power.

In medicine and life sciences, this transition became visible in the 1970s. Systems such as MYCIN at Stanford demonstrated that clinical decision support could be encoded into software, while INTERNIST-1 showed that even broad diagnostic knowledge could be organised computationally at scale. These systems were limited by static rules, manual knowledge engineering, and weak real-world deployability, but they proved a critical point: clinical expertise could be structured, interrogated, and supported by machines.

Why does this matter today? Because modern AI in clinical trials and life sciences is not a sudden disruption; it is the result of a long progression from logic, to learning, to prediction, and now to language and multimodal reasoning. The early era established the conceptual legitimacy of AI in medicine. Later phases enabled by digital records, genomic data, machine learning, deep learning, and foundation models turned that concept into scalable capability. Understanding where AI started makes it easier to understand why it is now influencing trial design, patient recruitment, monitoring, and drug discovery with far greater practical impact than earlier generations ever could.

> “AI began to formalise human reasoning. Its significance in clinical and life sciences lies in how that early idea evolved into systems that can now support scientific discovery, trial execution, and evidence generation at scale.

3. Rule-Based Foundations 1960s to 1990s

Early AI in medicine was strongly shaped by knowledge engineering, although it also evolved alongside statistical and probabilistic approaches. Early systems such as DENDRAL in scientific discovery and later MYCIN in clinical decision support showed that expert reasoning could be encoded in software for narrow, high-value tasks. MYCIN, initiated at Stanford in 1972, demonstrated near specialist-level performance in diagnosing bacterial blood infections and recommending antibiotic therapy, while INTERNIST-1 attempted to codify broad internal medicine knowledge at scale.

The limitation was equally clear: These systems were most effective within tightly defined domains and encoded rule sets. Because their knowledge was manually encoded, these systems did not learn directly from new data and required manual updating as evidence changed, nor did they translate easily into reliable, maintainable use within routine clinical workflows. Even so, they established the first enduring idea in clinical AI: medical reasoning could be formalised, supported, and partially automated.

4. Statistical Learning and Digitisation

1990s to 2005

The next shift moved AI from hand-coded rules to data-driven inference. Statistical models, Bayesian methods, and early neural approaches began learning patterns directly from data rather than relying only on expert-authored logic. In parallel, the Human Genome Project, completed in 2003, delivered the first near-complete reference sequence of the human genome roughly 3 billion base pairs helping lay the foundation for computational life sciences.

Clinical digitisation also started to matter. In imaging, the FDA approved ImageChecker M1000 in 1998, one of the earliest AI-assisted mammography CAD systems. Across hospitals, electronic records were still immature, but the data foundation for modern AI was being laid. By 2008, only 9% of US non-federal acute care hospitals had adopted a “basic” EHR by the narrow definition commonly used at the time.

5. Deep Learning Changes Clinical and Scientific Work 2006 to 2021

Deep learning changed the trajectory of AI in healthcare. Better computing power, larger datasets, and modern neural architectures enabled systems to perform competitively in image-rich tasks such as radiology and ophthalmology. CheXNet became a milestone by outperforming the average radiologist on the study's primary comparison metric, F1 score, for pneumonia detection on chest X-rays. Google's diabetic retinopathy model also demonstrated high sensitivity and specificity against ophthalmologist-based reference standards.

At the same time, AI began to reshape scientific discovery. In protein structure prediction, AlphaFold first placed first in CASP13 in 2018, and the later AlphaFold2 system demonstrated accuracy competitive with experimental structures in a majority of cases, expanding the practical role of AI in biology. This marked a shift from AI primarily as a support tool toward AI as a more direct accelerator of scientific discovery.

6. AI Begins to Reshape Trial Design

Late 2010s to Early 2020s

As clinical development became more expensive and operationally complex, AI started moving upstream into trial design. The most promising use cases emerged where complexity was high and manual processes were slow: eligibility criteria, cohort definition, endpoint strategy, and protocol optimisation. Reviews of the field consistently show that recruitment and design are among the earliest and most practical applications of AI in clinical trials.

A notable example is Trial Pathfinder, which used real-world data to simulate oncology trial eligibility. The study showed that relaxing some commonly used exclusion criteria could more than double the pool of eligible patients on average while having only a minimal effect on treatment-effect estimates. That insight matters: the future of better trials is not just faster execution, but smarter design before the first patient is enrolled.

7. Recruitment, Feasibility, and Site Intelligence 2020s

Recruitment remains one of the biggest points of failure in clinical development, and this is where AI has shown strong practical relevance. Recent reviews show that AI is being used to screen records, match patients to protocol criteria, and support recruitment and retention workflows. Most published work to date has focused on recruitment efficiency, especially in oncology and other data-rich care settings.

Site selection is also becoming more predictive. Real-world data and machine learning models are now being used to rank sites based on likely enrollment performance rather than relying only on historical intuition. Evidence from published modeling studies suggests that AI-supported site ranking can outperform standard baseline methods by combining historical recruitment patterns with local patient availability.

8. Monitoring, Risk, and Operational Quality 2020s to Present

The next wave of AI in trials is increasingly operational: risk prediction, anomaly detection, quality management, and monitoring prioritisation. Instead of treating monitoring as a uniform activity, AI can help teams identify where risk is rising, where data quality may be drifting, and where intervention is most needed. This aligns directly with the industry's move toward risk-based quality management.

Regulatory thinking is moving in the same direction. The final ICH E6(R3) Good Clinical Practice guideline, adopted in January 2025, explicitly supports flexible, risk-based approaches and recognizes the use of modern technologies and innovations in trial design, conduct, and oversight. In other words, AI is not replacing clinical quality disciplines; it is making them more targeted, more proactive, and more scalable.

9. Foundation Models and Clinical Language 2018 to 2023

A large share of clinically meaningful information lives in unstructured text: notes, pathology narratives, medical histories, protocol documents, safety narratives, and scientific literature. Transformer models changed what could be done with this material. BERT, and later domain-specific models such as ClinicalBERT, changed what could be done with this material by making clinical language more usable for computation and downstream analysis rather than leaving it as a documentation burden.

This matters for trials as much as for care. Foundation models are beginning to support tasks such as eligibility interpretation, literature synthesis, protocol design support, and trial-patient matching. In medical question answering, Med-PaLM became the first AI system to exceed a passing threshold on USMLE-style benchmarks, signaling that language models were beginning to handle complex biomedical reasoning tasks with increasing competence.

10. AI in Drug Discovery and Translational Science 2018 to Present

In life sciences, AI is now influencing the path from target discovery to molecule design to translational prioritisation. Its strongest impact has come from compressing early-stage search: identifying targets, predicting molecular properties, prioritising compounds, and helping researchers move from broad possibility to focused experimentation faster. Recent reviews show that AI is increasingly embedded across discovery and early development workflows. A visible milestone came when Insilico Medicine's INS018_055 entered Phase II clinical testing in 2023. While industry labels around "First AI-designed drug" should be treated carefully, the event clearly marked a new level of maturity:

> "AI was no longer only generating hypotheses, but also helping move candidates into patient studies.

11. Responsible Deployment in Regulated Environments 2023 to Present

As AI becomes more capable, the central question is no longer whether it can be used, but how it should be governed in regulated clinical and scientific environments. Concerns around bias, transparency, validation, data lineage, and human oversight are no longer theoretical. They directly affect participant safety, data credibility, and regulatory trust.

This is why governance is becoming part of the innovation stack. WHO's 2024 guidance on large multi-modal models in health outlined over 40 recommendations for governments, technology developers, and healthcare organisations. In parallel, ICH E6(R3) formalises a more risk-based, quality-by-design view of modern trial conduct. For clinical and life sciences organisations, responsible AI is not a brake on progress; it is the basis for adoption at scale.

12. Strategic Implications

The evolution of AI in this sector follows a broad pattern:

from encoded expertise, to statistical learning, to perception, to language, to multi-modality, and now toward more coordinated forms of decision support.

For clinical trials and life sciences, the most valuable applications are not the loudest ones. They are the ones that improve trial design, recruitment, site strategy, data quality, monitoring focus, scientific prioritisation, and regulatory readiness. The organizations most likely to lead are not those that simply adopt more AI, but those that combine scientific credibility, operational discipline, and responsible governance to apply AI where it creates measurable value.

13. About the Author

Prepared by: Boddu Sri Pavan
Role: Data Scientist-I
Focus areas: Clinical Data Science, Applied AI in clinical research, life sciences strategy, Algorithm Development

14. About IQA

Inductive Quotient Analytics (IQA) is positioned at the intersection of clinical execution, biometrics rigor, and AI-enabled operating models. IQA describes itself as an AI-powered full-service CRO and clinical technology partner, combining clinical development services, data science & AI, quality-led execution, and purpose-built platforms.

IQA's offering is lifecycle-wide: clinical development from preclinical through Phase I-IV and post-market, biometrics and related services spanning biostatistics, clinical data management, statistical programming, RWE/HEOR, and medical writing, plus technology platforms that support protocol design, site insights, randomization, data capture, data quality, data transformation, clinical insights, and eTMF workflows. In that sense, IQA's value proposition is not only that it uses AI, but that it combines services, platforms, and submission-ready clinical data capabilities in a single delivery model for sponsors, biotech teams, medtech innovators, and CRO stakeholders.

15. Closing Perspective

AI has crossed an important threshold in life sciences and clinical research. It began as a scientific concept, matured into data-driven prediction, proved value in biology, and is now becoming part of the execution layer of modern clinical development.

The leaders in this next phase will not be the organizations that adopt the most AI, but the ones that apply it where it improves protocols, recruitment, data quality, oversight, and decision-making under credible governance. **From that perspective, IQA's positioning appears directionally aligned with the Clintelligence Curve and positioned to help lead it.**

16. References

https://www.britannica.com/technology/MYCIN
https://pubmed.ncbi.nlm.nih.gov/365439/
https://pmc.ncbi.nlm.nih.gov/articles/PMC1307155/
https://link.springer.com/chapter/10.1007/978-1-4612-5108-8_8
https://people.dbmi.columbia.edu/~ehs7001/Buchanan-Shortliffe-1984/Chapter-01.pdf
https://doe-humangenomeproject.ornl.gov/history/
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P970058
https://www.diagnosticimaging.com/view/r2-garners-pma-approval-fda-imagechecker-cad-workstation
https://healthit.gov/data/quickstats/national-trends-hospital-and-physician-adoption-electronic-health-records/
https://pmc.ncbi.nlm.nih.gov/articles/PMC7481034/
https://arxiv.org/abs/1711.05225
https://pubmed.ncbi.nlm.nih.gov/27898976/
https://pmc.ncbi.nlm.nih.gov/articles/PMC6907002/
https://www.nature.com/articles/s41586-019-1923-7
https://www.nature.com/articles/s41586-021-03819-2.pdf
https://www.nature.com/articles/s43856-023-00425-3
https://pmc.ncbi.nlm.nih.gov/articles/PMC9974218/
https://link.springer.com/article/10.1007/s12553-023-00738-2
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0300109
https://academic.oup.com/jamia/article/31/11/2749/7755392
https://www.nature.com/articles/s41746-025-01886-7
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e6r3-good-clinical-practice-gcp
https://database.ich.org/sites/default/files/ICH_E6%28R3%29_DraftGuideline_2023_0519.pdf
https://arxiv.org/pdf/1904.05342
https://sites.research.google/gr/med-palm/
https://www.nature.com/articles/s41591-024-03423-7
https://www.cell.com/med/fulltext/S2666-6340%2824%2900308-8
https://www.nature.com/articles/d43747-022-00104-7
https://clinicaltrials.gov/study/NCT05938920
https://www.prnewswire.com/apac/news-releases/first-drug-discovered-and-designed-with-generative-ai-enters-phase-ii-trials-with-first-patients-dosed-301862737.html
https://iris.who.int/server/api/core/bitstreams/e9e62c65-6045-481e-bd04-20e206bc5039/content
https://pmc.ncbi.nlm.nih.gov/articles/PMC9974218/
https://www.nature.com/articles/s41746-025-01886-7
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e6r3-good-clinical-practice-gcp
https://www.tga.gov.au/resources/publication/corporate-reports/ich-guideline-good-clinical-practice

Contact Us

https://inductivequotient.com/contact/